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Hand osteoarthritis (OA) is a very frequent disease, but yet understudied. However, a lot of works have
been published in the past 10 years, and much has been done to better understand its clinical course and
structural progression. Despite this new knowledge, few therapeutic trials have been conducted in hand
OA. The last OARSI recommendations for the conduct of clinical trials in hand OA dates back to 2006. The
present recommendations aimed at updating previous recommendations, by incorporating new data.
The purpose of this expert opinion, consensus driven exercise is to provide evidence-based guidance on
the design, execution and analysis of clinical trials in hand OA, where published evidence is available,
supplemented by expert opinion, where evidence is lacking, to perform clinical trials in hand OA, both for
symptom and for structure-modiﬁcation. They indicate core outcome measurement sets for studies in
hand OA, and list the methods and instruments that should be used to measure symptoms or structure.
For both symptom- and structure-modiﬁcation, at least pain, physical function, patient global assess-
ment, HR-QoL, joint activity and hand strength should be assessed. In addition, for structure-
modiﬁcation trials, structural progression should be measured by radiographic changes. We also pro-
vide a research agenda listing many unsolved issues that seem to most urgently need to be addressed
from the perspective of performing “good” clinical trials in hand OA. These updated OARSI recommen-
dations should allow for better standardizing the conduct of clinical trials in hand OA in the next future.
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Hand osteoarthritis (OA) is a subtype of OA that receives rela-
tively little attention, when compared to knee and hip OA1. It is
responsible for a considerable clinical burden in terms of disability
and reduction of quality of life2. Since hand OA has a poly-articular
nature and therefore is complex to study, it warrants special
attention1,3. Furthermore, hand OA is not one homogeneous
phenotype, but consists of several phenotypes, including inter-
phalangeal OA, thumb base OA and erosive OA, with different
treatment options4,5. In recent years the number of clinical trials in
the ﬁeld of hand OA has increased leading to new insights and
generation of new research data6e8. Therefore, an update of the
recommendations for the conduct and design of clinical trials in
hand OA is needed9. The Osteoarthritis Research Society Interna-
tional (OARSI) has set-up a Task Force for this purpose, which was
composed of academic physicians, clinical physicians and re-
searchers from both academia and pharmaceutical industries, all
with interest and expertise in hand OA.
The Task Force updated the recommendations that were pub-
lished in 20069. The present manuscript will focus on the speciﬁc
aspects that should be taken into account in developing a clinical
trial in hand OA. More general recommendations for the conduct
and design of clinical trials in OAwill be described elsewhere in this
issue. The update is based on published medical literature sup-
plemented by expert opinion. The guidelines by CONSORT
(Consolidated Standards of Reporting Trials) were an important
starting point10. Furthermore, we have taken into account guide-
lines from the regulatory agencies; for pharmacological treatment
this included both the Food and Drug Administration (FDA)
and the European Medicines Agency (EMA) developed guidelines
http://www.ema.europa.eu/ema/pages/includes/document/open_
document.jsp?webContentId¼WC500003440 London, 20 January
2010, Doc. Ref. CPMP/EWP/784/97 Rev. For devices only the FDA has
done so (http://www.fda.gov/downloads/Drugs/GuidanceCompliance
RegulatoryInformation/Guidances/ucm071577.pdf). For the current
recommendations, the EMA guidelines were of particular interest,
since the FDA guidelines speciﬁcally focus on the treatment of
knee and hip OA. Furthermore, the Task Force took advantage of
results from a working group from OMERACT addressing the
development of core outcome measurement sets for studies in
hand OA11,12. The Task Force met in whole, or in part, on three
occasions over a 2-year period between 2013 and 2014. Additional
modiﬁcations of the recommendations were made through tele-
conferences and e-mail correspondence. The ﬁnal recommenda-
tions were submitted to the OARSI steering committee for clinical
trial recommendations in OA, for approval, prior to submission to
Osteoarthritis and Cartilage for independent external review, and
publication.
The development of the methodology for performing clinical
trials for hand OA is a work in progress and will evolve as more
information becomes available. Investigators and representatives of
regulatory and sponsoring agencies should be aware that the
following recommendations will need to be continually updated by
the most current research. New methodologies will need to be
incorporated into protocol design. The Task Force is of the opinion
that changes in protocol design should be based on published data.
The Task Force recommends that developers of new protocols
should utilize instruments that are valid, sensitive to change and
reliable, feasible to use, including being public availability for the
research community, and clinically relevant for primary outcome
assessments.Objectives for treatments of hand OA to be investigated in
clinical trials
Effective treatment for hand OA may alter symptoms and/or
modify structure and pathology. Treatments can be pharmacolog-
ical, such as analgesics, and non-pharmacological, such as devices
or hand exercise or patient education. Demonstration of the ben-
eﬁts will depend upon the objective of the trial, trial design, sample
size, randomization, blinding, study population and outcome
measurements. In particular, the selection of the study population
and the outcome measures speciﬁc for hand OA clinical trials will
be discussed in this manuscript.
The term symptom modifying drug or intervention will be
appropriate for therapies directed at modifying symptoms, mostly
pain and function. Symptom modifying drugs may relieve symp-
toms quickly or slowly; the latter are referred to as symptomatic
slow acting drugs for OA (SYSADOA). These different types of
symptom modifying drugs require speciﬁc trial designs. Notably,
symptom modifying drugs should not have clinically signiﬁcant
adverse effects on joint structure.
A structure (disease)modifying drug or interventionmay have
effects on joint structure independent of any direct effect on
symptoms. Studies of therapeutic interventions that are expected
to modify the pathologic process of hand OA should measure out-
comes that reﬂect an alteration in joint structure. Such treatments
may prevent the development of hand OA or change the course of
hand OA, once it has developed. The latter category includes ther-
apeutic interventions that may have the potential to stop pro-
gression, retard progression, or reverse existing hand OA
abnormalities. Symptomatic improvement may occur secondary to
structural beneﬁts.Patient selection
Source of patient recruitment
It is crucial to deﬁne the settings and locations (primary, sec-
ondary, or tertiary care or from the community), from which
eligible subjects will be recruited. Hand OA is a disease that is
highly prevalent and is common in the community13,14. Not all in-
dividuals with symptoms and signs of hand OA consult a physician
or are referred to secondary care. An observational study in the
community showed that health related quality of life (HR-QoL) in
patients with hand OA is similar to healthy individuals15, whereas
patients with hand OA studied in a hospital setting have a clinical
burden that is similar to that of patients with rheumatoid
arthritis16,17. Clinical trials in different settings, such as general
practice vs a tertiary care center, can lead to different results18,19.
Also, a trial in one specialized center vs a multicenter study could
yield different results. Settings and locations are important de-
terminants of the applicability and generalizability of the trial.Hand OA state under investigation
Hand OA diagnosis
Criteria for the classiﬁcation or diagnosis of hand OA should be
clearly described. Patients should have symptoms and structural
signs of hand OA. Preferably, patients should fulﬁll validated criteria
for the classiﬁcation or diagnosis of hand OA, such as those pub-
lished by the American College of Rheumatology (ACR) (Table I)20
or by the European League against Rheumatism (EULAR)4.
Table I
Classiﬁcation criteria for osteoarthritis of the hand developed by the ACR subcom-
mittee on criteria for osteoarthritis (diagnostic and therapeutic criteria committee of
the council on research)20
Hand pain, aching, or stiffness
And
3 or 4 of the following features:
Hard tissue enlargement of 2 or more of 10 selected joints
Hard tissue enlargement of 2 or more DIP joints.
Fewer than three swollen MCP joints.
Deformity of at least 1 of 10 selected hand joints
The 10 selected joints are the second and third DIP, the second and third PIP, and the
ﬁrst CMC joints of both hands. This classiﬁcation method yields a sensitivity of 94%
and a speciﬁcity of 87%. MCP ¼ metacarpophalangeal.
M. Kloppenburg et al. / Osteoarthritis and Cartilage 23 (2015) 772e786774Hand OA phenotypes
Hand OA consists of different phenotypes4,5. Thumb base OA
that affects primarily the trapeziometacarpal joint or ﬁrst carpo-
metacarpal joint often in conjunction with OA in the scapho-
trapezial joint, may exist alone, but often occurs together with OA
in the interphalangeal joints21,22. Interphalangeal OA, clinically or
radiologically deﬁned, is often accompanied by Heberden and/or
Bouchards nodes and then referred to as nodal OA4. Thumb base OA
is considered to be more biomechanically driven23,24 and particu-
larly contributes to the experience of hand pain21,25. Furthermore,
treatment options for thumb base OA are distinct from those for
interphalangeal OA (e.g., splints, surgery)26,27. Thus, protocols may
study thumb base OA as a speciﬁc phenotype. However, it should be
noted that one of the main shortcomings within the ACR hand OA
classiﬁcation criteria is that all hand OA phenotypes are lumped
together, making no distinction among different subtypes; this
could result in a heterogeneous study population. Therefore, it is
suggested that additional inclusion criteria be added to deﬁne the
distinct entity of thumb base OA in case this phenotype is to be
speciﬁcally addressed in clinical hand OA trials. Currently, new
hand OA criteria are being elaborated that address interphalangeal
OA and thumb base OA separately. These will become available in
the coming years.
Although recent MRI studies suggest that subchondral erosions
are much more common than previously considered28, erosive
interphalangeal OA has traditionally been considered to be a rela-
tively uncommon phenotype29e31. Whether it is a separate disease
entity from nodal interphalangeal OA, or a more severe form or
advanced stage of the same disease process, is not clear at the
moment, but it results in a high clinical burden5,32,33,34. No formal
classiﬁcation criteria exist to deﬁne erosive OA. Currently, erosive
OA is a radiographically deﬁned phenotype. Several validated
scoring systems exist that deﬁne erosive interphalangeal joints (see
also below)35e37. Observational studies have demonstrated that the
presence of one erosive interphalangeal joint increases the clinical
burden of the patient with hand OA, suggesting that presence of a
single erosive joint is sufﬁcient to classify an individual as having an
erosive disease phenotype30. However, some researchers require at
least two erosive joints as the criteria for an erosive disease
phenotype32,38. At present, for clinical trials use, no uniformly
agreed upon deﬁnition of erosive interphalangeal OA is available.
Use of a validated radiographic score is recommended to deﬁne an
erosive interphalangeal joint and a description should be included
of the required number of erosive interphalangeal joints necessary
for a subject to be included in the particular clinical trial protocol.
Since not all researchers deﬁne joint erosions in the same way, it
would be very helpful to provide representative illustrations and/or
images of erosive hand OA by the authors in the protocol and ﬁnal
published report of the clinical trial to aid representation across
studies. These actions would help to better standardize the phe-
notypes in the trials.Finally, patients with secondary OA (e.g., post-traumatic
arthritis, calcium pyrophosphate deposition disease, hemochro-
matosis), or patients with exacerbating factors related to primary
OA (e.g., inﬂammatory or genetic factors) can be the focus of study
and included in a clinical trial. A factor of interest is hypermobility,
whose presence has been shown to be associated with thumb base
OA39 and with protection of OA in the proximal interphalangeal
(PIP) joints40. Hypermobility decreases with age so this risk factor is
of particular interest in younger patient cohorts. If selected groups
are studied, the underlying condition should be speciﬁed, and the
selection features should be standardized in all included subjects.
Study joint(s)
Since hand OA is a poly-articular disease, protocols should
specify the primary joint or region to be studied; i.e., both hands,
the more symptomatic hand, the dominant hand, a single joint, a
single ray, and a single row of joints. This is in contrast to the study
of OA in knees or hips, where it is recommended that a single joint
be pre-speciﬁed as a target joint for evaluation.
Clustering of OA occurs within the hand; hand OA also occurs
with OA at other joint sites. The strongest and most consistent
association has been found between hand OA and the presence and
future occurrence of knee OA22,41,42,43. Progression of hand OA
clusters between hand joint groups as well as in a symmetrical
pattern and in rows, but not in rays44. An association exists be-
tween progression in hand OA and knee OA, both in individuals
from the community, as in patients with hand OA in a hospital
setting44,45. This clustering of joints with progression provides
opportunities for studying multiple joint sites simultaneously in a
clinical trial, especially hand OA together with knee OA, and sup-
ports the inclusion of multiple hand joints of one individual in a
clinical trial in hand OA. Results from simultaneous assessment of
joints might generate supportive evidence for ‘general’ OA
efﬁcacy46.
In case several hand joints within a patient are the focus of
study, more observations per patient are available and thereby
statistical power can be increased above that which is provided
simply by the total number of patients However, the observations
of hand joint in the same patient are not independent observations
and therefore in statistical analyses this has to be accounted for,
with appropriate statistical methodologies such as with the use of
generalized estimating equations. In all cases, information on the
status and evolution during the study of the other hand joints that
are not being speciﬁcally investigated should be appropriately
recorded.
Radiographic disease state
Although hand OA can be classiﬁed based on symptoms and
signs only20 and symptoms have only limited overlap with radio-
graphic signs14, radiographic information can help to deﬁne the
disease state and eventually increase the applicability and gener-
alizability of the results and the selection of the study population
most likely to beneﬁt from the intervention under study. For
example, a subject with advanced radiographic abnormalities
might be appropriate for studies of a symptom modifying drug,
while subjects with minimal radiographic abnormalities would be
more appropriate for studies of a structure modifying drug inten-
ded to retard progression.
A single postero-anterior radiograph of both hands, with the
hands parallel on the same cassette, is acceptable to deﬁne the
radiographic state in a symptom modifying trial or to screen the
radiographic state in a structure modifying trial at baseline.
Grading by Kellgren and Lawrence47 in 1957 and illustrated in
their Atlas of Standard Radiographs is a composite index that has
been used for many years to deﬁne radiographic abnormalities.
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grading scheme have been noted48. These limitations include over-
emphasis on the osteophyte as a marker of disease, and indicator of
its severity, and difﬁculties in interpretation, leading to poor inter-
observer and inter-site agreement. In an attempt to address some of
these limitations of a global grading scale, additional radiographic
grading methods have been developed, which focus on individual
radiographic features of OA at speciﬁc joint groups35,36.
Currently, there is no agreement on the way to describe radio-
graphic severity of hand OA at the individual patient level. This is an
important aspect that should be elaborated upon in the coming
years. The Task Force agreed to recommend that a recent radio-
graph should be obtained upon entry into a symptommodifying or
structure modifying trial. To characterize radiographic severity of
subjects in trials at baseline for purposes of a symptom modifying
trial, it is recommended that a radiograph should be obtained
within the prior 6months. However, depending on the intervention
under study and the expected effect on structure, in structure
modifying trials, where radiographic damage is the main outcome
subdomain, radiographs should be obtained at baseline or at
screening, with the maximum time elapsed between screening and
baseline no longer than 4 weeks.
In trials of structure modiﬁcation, the study population should
have a Kellgren and Lawrence radiographic grade of 2 or 3 (or
equivalent) in the hand joint(s) to be studied.
For more information see also elsewhere in this journal.49
Clinical disease state
In trials of symptom modiﬁcation, minimum levels of symptom
severity for both pain and/or function and symptom duration
should be speciﬁed. Patients should have pain and tenderness in at
least two interphalangeal or one 1st CMC joint, or in a combination
of interphalangeal and 1st CMC joints. Pain should have been pre-
sent for at least half of the days in the previous month and for at
least 48 h prior to the screening visit. To ensure that reported pain
is associated with OA, it is recommended that pain is present in a
joint that has been demonstrated to have OA on a plain radiograph.
There is no current consensus on the minimum and maximum
pain level required for study entry. It is proposed that on entry to a
study there be a hand pain score of 40e80 mm on a 100 mm Visual
Analog Scale (VAS) or 4 to 8 on an 11 point Numerical Rating Scale
(NRS) (0 ¼ no pain; 10 ¼ extreme pain) after withdrawal of
analgesic/anti-inﬂammatory medications, which is what is
currently required in study design of OA clinical trials. The mini-
mum threshold is in accordance with the “Patient Acceptable
Symptom State”50. There is also no current consensus on the min-
imum level of disability on entry. However, for one of themost used
instruments in physical function assessment, the Functional Index
for Hand OsteoArthritis (FIHOA, range: 0 e 30), it has been shown
that a score of at leastﬁve discriminated between non-symptomatic
and symptomatic patients51; therefore, aminimum level of six could
be used. The minimum level of disability will depend on the study
intervention (symptom modiﬁcation vs structure modiﬁcation).
Additional considerations are whether there is sufﬁcient room
for clinically relevant improvement (i.e., ceiling or ﬂoor effects) and
whether it is likely that the clinical disease state is responsive52. To
ensure the latter, a “ﬂare design” can be used. In a “ﬂare design” a
chronically used intervention (mostly oral NSAID) is discontinued
during the screening phase. Study entry is dependent upon a pain
ﬂare of a predetermined amount occurring within a short period of
time (e.g., 48 h) after withdrawal of the intervention. No evidence
exists for the minimal level of worsening in pain, but mostly þ20
or þ30 mm on a 0e100 mm VAS is required. Further studies are
needed to investigate the minimal level of change required to
deﬁne a ﬂare (see also under “Flares”).Hand OA at risk for progression
Although it might jeopardize the generalization of the results,
for studies of structuremodifying agents, it may be advantageous to
study special subpopulations of subjects, who are at high risk for
development of OA, or rapidly progressive OA. Currently, no
consensus exists on which hand OA patients are especially at risk.
Only limited numbers of longitudinal studies have investigated risk
factors for clinical and radiographic progression53. It was
concluded, based on a systematic review, limited to four studies
that a positive association exists between an abnormal scinti-
graphic scan and radiographic hand OA progression53. However,
scintigraphic scans are not readily available at all investigative sites
and the examination is time consuming and expensive. Therefore,
the Task Force does not recommend the routine use of scintigraphic
scans for structure modifying trials to select patients at risk of
radiographic progression. In the systematic review, many de-
terminants were identiﬁed as having a positive association with
radiographic progression; however most associations were only
based on one single high-quality study. Examples of baseline risk
factors are number/intensity of painful OA joints, presence of
erosive OA or nodal OA, number of osteophytes, early menopause,
serum level of adiponectin and accelerated bone mineral density
loss. Examples of risk factors for the evolution of erosive OA are
number/intensity of painful joints, joint space narrowing (in J-
phase as deﬁned in the anatomical phases scoring system from
Verbruggen (see below)) and familial clustering53. However, more
data will have to become available before deﬁnite recommenda-
tions can be made on this issue.
Recently, it has become clear that inﬂammatory signs, as
assessed by physical examination, ultrasonography and MRI, are
cross-sectionally associated with more symptoms and longitudi-
nally with more radiographic progression54e57. The waxing then
waning course of inﬂammation in the longitudinal disease process
may explain the paucity of symptoms with severe radiographic
severity58. One study suggested that clinically swollen joints at
baseline were associated with erosive evolution. Two studies sug-
gested that synovial inﬂammation is associated with radiographic
progression, and one study suggested that bone marrow lesions
were associated with radiographic progression. However, further
studies have to be done before recommendations can be made for
these promising predictors. Before more evidence becomes avail-
able about the value of inﬂammatory signs (including clinically
assessed soft tissue swelling), as predictors of radiographic pro-
gression, these determinants could be considered exploratory for
purposes of clinical trials; this in turn will generate evidence that
may in future elevate such determinants to the level of primary
outcomes.
Inclusion and exclusion criteria
Table II summarizes the main inclusion and exclusion criteria to
be considered at entry.
Inclusion criteria should be clearly deﬁned and should specify,
apart from the source of recruitment of study participants and their
hand OA state (diagnosis, hand OA phenotype, clinical and radio-
graphic disease state), demographics such as age and gender.
Exclusion criteria should also be clearly deﬁned. Homogeneity
of the study population should be considered with regard to the
presence of primary or secondary OA. It is suggested that patients
with OA secondary to known causes (e.g., gout, rheumatoid
arthritis, psoriatic arthritis, to name a few) should be excluded from
studies of patients with primary/idiopathic OA.
Co-morbid diseases, as well as previous conditions of concern
(such as peptic ulcer disease, if a drug is perceived to have ul-
cerogenic potential) should be taken into account, and could result
in speciﬁc exclusion criteria, depending on the study intervention.
Table II
Summary of inclusion and exclusion criteria for hand OA clinical trials
Criterion Symptom-modifying trials Structure-modifying trials
Inclusion
Diagnosis Preferably according to ACR or EULAR criteria Same
Phenotype Description of IP OA, thumb base OA, or erosive OA Same
Demographics Age range Gender, Same
Clinical disease state Pain: 40 to 80 on 100 mm VAS Function: 6 on FIHOA NA
Radiological disease state NA 1 radiographically affected joint
(KL 2 or 3, or equivalent)
Exclusion
Secondary OA
Hand/upper limb disorders
Comorbid diseases
Concomitant medication
Radiological disease state
Such as gout, hemochromatosis, rheumatoid/psoriatic arthritis
Psoriasis
Such as poly-articular chondrocalcinosis, thoracic outlet syndrome,
carpal tunnel, Guyon's canal syndrome, cubital tunnel syndrome,
diabetic neuropathy or cheiroarthropathy, palmar tenosynovitis,
trigger ﬁnger, ﬁbromyalgia, pain syndrome, injury in joint(s) within past 6 months
Depending on intervention, such as peptic ulcer, renal impairment,
hepatic dysfunction, hematologic disease, cancer
IA steroids in past month
IA HA within past 6 months
Analgesics unless stable dosage for 1 month
Sy-SADOA unless stable dosage for 3 months
NA
Same
Radiographic end-stage in target joints
Abbreviations: ACR; EULAR; IP; VAS; FIHOA; NA ¼ Not applicable, KL ¼ KellgreneLawrence, IA ¼ intra-articular, Sy-SADOA ¼ symptomatic slow-acting OA drug.
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unless at a stable dosage for at least 1 month for analgesics or 3
months for slow acting symptomatic or structure modifying drugs
(Sy-SADOAs or DMOADs), and recent treatment with intra-articular
corticosteroids is also recommended. A minimum period of 1
month should elapse between the time of the intra-articular in-
jection of a depot corticosteroid and enrollment in a trial. There
should be at least a 6-month interval between the time of intra-
articular injection of a hyaluronate and enrollment in a trial. The
necessity for, and appropriate duration of, a wash-out period (e.g.,
3e6 months) for slow acting symptom modifying drugs should
always be considered, especially when the study drug itself is a
slow acting drug for symptom relief.
Additional recommended exclusions include the following:
signiﬁcant injury to the affected joint within 6 months of trial
enrollment; concomitant rheumatic disease (e.g., inﬂammatory
rheumatic disease, cutaneous psoriasis, poly-articular chon-
drocalcinosis, gout, carpal tunnel syndrome, palmar tenosynovitis,
trigger ﬁnger, ﬁbromyalgia, pain syndrome, Guyon's canal syn-
drome, thoracic outlet syndrome, cubital tunnel syndrome, diabetic
neuropathy or cheiroarthropathy), or poor general health likely to
interfere with compliance or assessment. It has to be noted, that
when the study population will become more homogeneous the
results will be less generalizable and less variable, so imple-
mentation and prediction will be compromised.
Description of patient characteristics at baseline
At a minimum, sociodemographic and clinical data collected at
the time of enrollment into the study should include age (date of
birth), gender, symptom duration, current or past activities
involving intensive use of the hands (e.g., sports, gardening, playing
speciﬁc musical instruments), and previous and concomitant ther-
apies. Additionally, it is suggested that the following information be
collected at study entry: height, weight, years of formal education,
patients' primary occupation, comorbidities, menopausal status in
women, and OA at other joint sites (such as knee or hip).
Description of the target joints at baseline
Baseline information about the target joint or joints helps to
characterize the study population. However, it has to be mentioned
that at the moment, no valid and reliable instruments exist toassess most clinical aspects of the joints (see also below). Despite
this lack of instruments, the Task Force recommended performance
of a complete standardized history and physical examination of
hand joints at baseline, including the following: the description and
number of self-reported symptomatic joints (e.g., painful joints),
the description and number of tender joints upon palpation, the
description, location and number of Heberden and Bouchard nodes,
joints affected by lateral deviation, subluxation of the 1st thumb
metacarpal, joint lateral/medial instability, and the number of
inﬂamed joints as deﬁned by soft (peri-)articular tissue swelling on
palpation (i.e., capsulosynovial thickness) sometimes accompanied
by redness. Although there is no current consensus of a standard-
ized method to assess soft tissue swelling in hand OA, we strongly
believe that this clinical sign is of high importance. We therefore
recommend that this assessment should be done on all hand joints,
at least at baseline, to better describe the study population and to
enable further exploratory analyses. To facilitate evaluation,
descriptive diagrams can be used.
Aesthetic damage is a frequently reported complaint of many
hand OA patients38. Therefore, a baseline assessment of this clinical
feature could be performed, both for description of the study
population and for eventual exploratory analyses.
General physical examination
Depending on the intervention, a general physical examination
should be performed at the onset of the study and again at the end
of the study.
Informed consent
Informed Consent should be obtained and documented in
accordance with the latest revision of the World Medical Associa-
tion Declaration of Helsinki, Fortaleza Brasil, October 2013 (http://
www.wma.net/en/30publications/10policies/b3/i). All studies
should be approved by an appropriate institutional review board.
Outcome measures for symptom modifying trials
Core domains and their instruments
Consensus on a core set of domains for OA clinical trials was
reached at the Outcome Measures in Rheumatology Clinical Trials
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subsequently ratiﬁed by the OARSI Task Force on Clinical Trials
Guidelines20. The core set of domains speciﬁed in the original
OMERACT and original OARSI Task Force OA Clinical Trials Guide-
lines were the following: pain, physical function and patient global
assessment; and for studies 1 year in duration, joint imaging. The
OARSI Task Force on design and conduct of clinical trials for hand
OA described additional domains including mobility, deformity,
inﬂammation, performance, stiffness and aesthetic damage9.
However, these core domain sets have several shortcomings;
namely patients were not involved in the selection process, only the
clinical trial setting was addressed, and the core sets incorporated
insufﬁciently the speciﬁc aspects of hand OA, such as its poly-
articular and heterogenic character. Therefore, in 2010, an OMER-
ACT hand OA working group was assembled, comprising health
professionals, researchers and patient research partners, with in-
terest and experience in hand OA11. This working group aimed at
deﬁning a new set of core domains using the OMERACT framework.
Based on Delphi exercises and discussions at several meetings,
including OMERACT11 and OMERACT12, a new core set of pre-
liminary domains has been endorsed for both symptom modifying
and structure modifying trials (Fig. 1)11,12. It was agreed that both
trial settings should contain at least pain, physical function, patient
global assessment, HR-QoL, joint activity and hand strength (see
below for detailed discussion). HR-QoL is part of the core domain
set, but this domain is not mandatory until there is a disease spe-
ciﬁc instrument available for measuring it as a single domain.
Instruments used to measure outcomes in clinical trials of hand
OA should be valid, reliable, responsive to change, feasible, and
publicly available, without mandatory payment for use. Preferably,
clinical trials in hand OA should use instruments that have been
used in previously published studies, thus permitting comparison
of results across trials of different therapeutic interventions and
enabling the performance of meta-analyses in systematic reviews.
Many clinical tools to assess symptoms in hand OA are available.
The instruments available for use in hand OA clinical trials are
discussed below by domain.
Pain
The measurement of pain is a core outcome domain. To assess
pain, a variety of instruments exist and have been used in hand OA
studies (Table III), including both disease speciﬁc instruments, such
as a Visual Analog Scale (VAS) or NRS60, Australian Canadian hand
OA Index (AUSCAN)61,62 or Score for Assessment and Quantiﬁcation
of Chronic Rheumatoid Affections of the Hands (SACRAH)17, but
also hand disorder or arthritis speciﬁc instrument, such as the
Michigan Hand Outcomes questionnaire (MHQ)63. The metric
properties have been more widely tested for some instruments
than for others. The VAS or NRS and AUSCAN pain are the most
extensively studied64.
To assess hand pain by a 100mmVAS, a standard question could
be asked e.g.,: “how much pain in your hand did you experience
during the past 48 h?”.
Since pain may vary dramatically over time and “jump” from
one joint to another, it can be helpful to assess pain over deﬁned
periods of time with the use of personal daily diaries where pa-
tients are asked to record the amount of pain in the target hand, or
by using a “weekly self-assessment of painful joints”. However
these methods are not validated yet65. VAS or NRS pain has good
validity and responsiveness64. The AUSCAN pain subscale, either in
its Likert or VAS format, has good metric properties, however it is
not freely available in the public domain (copyrighted).
During OMERACT12 the available instruments to measure pain
were discussed and the VAS or NRS pain were agreed upon as therecommended preliminary instruments for assessing pain12. How-
ever, clariﬁcation is needed concerning the assessment of overall
hand pain vs joint speciﬁc pain and the phrasing of the question.
Table V summarizes evidence from at least three studies for the
most frequently applied instruments for evaluation of pain in hand
OA64.
The Task Force therefore recommends the use of the single
question pain VAS or NRS as the main outcome measure for pain in
hand OA clinical trials. The VAS or NRS pain can also be used to
select patients.
Physical function
The measurement of physical function is a core domain. Hand
strength is a separate core domain and not included in the core
domain physical function (discussed below). To assess physical
function, many instruments exist and are used in hand OA studies
(Table III). To assess physical function questionnaires can be used,
which can be both disease speciﬁc, such as VAS or NRS60, AUS-
CAN61,62 Cochin scale66, Functional Index for Hand OA (FIHOA)51,67,
SACRAH17, or hand disorder or arthritis speciﬁc, such the Arthritis
Impact Measurement Scale (AIMS)68, Canadian Occupational Per-
formance Measure (COPM)69, Health Assessment Questionnaire
(HAQ)70 or MHOQ63. Performance-based instruments, that are not
disease speciﬁc, are also available; these include the Arthritis Hand
Function Test (AFHT)71, Dexterity test, Grip Ability Test (GAT)72 or
Moberg Picking Up Test73. The metric properties are more exten-
sively tested for some instruments than for others. Performance-
based tests, in particular, have been rarely studied and not all
their metric properties are studied in hand OA. Moreover, its use
requires speciﬁc devices, trained investigators, and it is time
consuming. Moreover, performance tests measure different do-
mains simultaneously, such as within the AHFT exploring both
aspects of hand function and performance, such as grip strength
and pinch grip.
Of the self-reported questionnaires the AUSCAN and FIHOA are
most extensively studied64. (Visser et al. manuscript on systematic
review of instruments for hand OA, submitted), and showed good
reliability, sensitivity to change and validity. For FIHOA feasibility is
good, taking an average of 136e165 s for completion depending on
the disease stage51; however some items are rather gender role-
speciﬁc (e.g., men use screwdrivers and women sew), culture
dependent (e.g., handshake) and have low secular relevance, (e.g.,
writing for a long period of time vs typing on computer (see Table V
for the list of items)). Both instruments are available and validated
in many languages. Because, the AUSCAN is not publicly available
without payment, a new instrument, accessible without payment,
is warranted to assess physical disability. During OMERACT12 the
available instruments to measure physical function were discussed
and the FIHOA was agreed upon as the preliminary instrument to
assess physical function12. Table IV summarizes supporting evi-
dence from at least three studies for the most frequently applied
instruments for evaluation of physical function in hand OA64.
The Task Force recommends including at least the FIHOA in-
strument to assess physical function in hand OA trials; adoption of
this recommendationwill facilitate comparison between studies or
performance of meta-analyses. In addition, AUSCAN may be used
(but may require either payment or authorization) if one accepts to
pay for use. Performance tests can add additional information and
can be added as exploratory outcome measures.
Patient assessment of global status
The patient's assessment of his/her global status should be
measured using a Likert, NRS or VAS. There is currently no validated
Fig. 1. Core set of preliminary domains endorsed at OMERACT12. (Report of OMER-
ACT12 ms. submitted to J Rheumatol). Domains for all settings, being clinical trials of
symptom or structure modiﬁcation, or observational studies. Domains for clinical
trials of structure modiﬁcation and observational studies.* Domains currently not
mandatory, since no reliable, valid or disease-speciﬁc instrument is available.
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this measure6,74,75. The optimal method by which this should be
measured is not well established. However, a standard question can
be used asking the following, “Considering all the ways your hand
OA affects you, how have you been during the last 48 h?”. DespiteTable III
Instruments measuring pain, physical function or patient global assessment in hand ost
Domain Speciﬁcations
Questionnaires
AIMS-268 Physical function 78 items, rated on 5 point scale.
ﬁnger function.
ASES120 Pain, physical function 20 items, scored 10 (very uncerta
scored by taking mean of subsca
AUSCAN61,62 Pain, physical function,
global assessment
15 items, Likert (0, none e 4, ext
0e100), stiffness (0e4/0e100), fu
Cochin scale66 Physical function 18 items, rated on Likert scale (0
COPM69 Physical function Interview on most important act
Subscale scores range 0 (not able
FIHOA51,67 Physical function 10 items, range 0 (no difﬁculty) e
Total score range 0e30. Original,
HAQ70 Physical function 20 items. Total score range 0e3 (
MAP-hand121 Physical function 18 items, range 0 (no difﬁculty) e
Total mean score calculated.
MHQ63 Pain, physical function, 37 items, rated on 5 point Likert
Scores normalized to 0-100 scale
OMFAQ122 Physical function 5 domains of functioning, scored
ADL scale.
PRWHE123 Physical function 15 item scale, rated on 0e10 NRS
Revel functional index124 Physical function 10 questions, rated 0 (without di
Total score range 0e20.
SACRAH17 Pain, physical function 23 questions, rated on VAS scale. 3
VAS/NRS/Likert125 Pain, physical function,
global assessment
Used for assessment of pain, pati
Performance-/assessor-
based instruments
AHFT71 Physical function 11-item test, 4 subscales: grip/pi
Button Test126 Physical function Unbutton and button 5 buttons,
Score recorded in seconds.
Dexterity Physical function Assessed using dexterity/purdue
GAT72 Physical function Modiﬁcation of Grip Function Tes
HFI127 Physical function 9 wrist/hand items from Keitel F
(much difﬁculties).
Total score 0e52 (0e26 for each
JTHFT128 Physical function 7 items, timed in seconds. Summ
MPUT73 Physical function Picking up 10 items and placing
Abbreviations: AHFT, AIMS-2, ADL ¼ activities of daily living, OARS ¼ Older Americans'
Canadian Hand OA Index, COPM, FIHOA, GAT, HAQ, HFI ¼ hand functional index, JTHFT ¼
MHQ, MPUT ¼ Moberg Picking Up Test, NRS ¼ numeric rating scale, OMFAQ ¼ OARS (O
Questionnaire, PRWHE ¼ Patient-Rated Wrist/Hand Evaluation, ROM ¼ Range of motion
(Modiﬁed from Visser AW et al., 201464).the limitation of the method, patient global assessment is a core
outcome domain. The proposed formulation should be validated
through further studies.
Quality of life
Measurement of HR-QoL, at appropriate intervals, is recom-
mended. During OMERACT12 there was consensus that HR-QoL is a
core outcome domain. However, at the moment there is no disease
speciﬁc instrument available and therefore the domain is currently
not mandatory. Examples of HR-QoL instruments include the Short
Form-36 (SF-36)76, Nottingham Health Proﬁle (NHP)77,78 and
EuroQol79,80.
HR-QoL questionnaires not only allow measurement of the pa-
tient's quality of life, but also the utility of their health status, and
therefore also facilitate pharmaco-economic analyses and cross-
disease comparisons of outcome. To date, there is little experi-
ence with these instruments in hand OA trials. Utility can be
measured using the EuroQol or Health Utilities Index (HUI)79e82.
Joint activity
It is recognized that processes, especially inﬂammatory pro-
cesses such as synovitis, take place and generate pain and softeoarthritis studies
Transformed into 12 scales, score range 0e10 (worst possible). 1 scale for hand/
in) e 100 (very certain to can do). 3 subscales: pain/function/other symptoms,
le items (range 10e100).
reme)/VAS version. Summed into 3 subscales: pain (Likert range 0e20/VAS range
nction (0e36/0e100).
, without difﬁculty e 5, impossible). Summed to ﬁnal score, range 0e90.
ivities. Five most important activities scored for performance/satisfaction (1e10).
to do/satisﬁed) e 10 (extremely able to do/satisﬁed).
3(impossible).
VAS, Likert version.
higher score indicates poorer functioning).
4 (not able to do).
(1, very good e 5, very poor).
.
1 (excellent) e 6 (total impaired). Total score range 5e30. Physical/instrumental
. Summed to subscales: pain (0e50), disability (0 e 60).
fﬁculty) e 2 (impossible).
domains: functional status, stiffness, pain. Original, Short-Form,Modiﬁed version.
ent global assessment, functioning, perceived strength, etcetera.
nch strength, dexterity, applied dexterity, applied strength. Score per subscale.
using a standard board.
pegboard
t. 3 items, timed (sec) and summed to total GAT score. GAT score <20 s ¼ normal.
unction Test, measuring motion patterns. Items ranged 0 (no difﬁculties) e 3
upper extremity)
ed to total score.
in container, timed in seconds.
Resources and Services, ASES ¼ Arthritis Self Efﬁcacy Scale, AUSCAN ¼ Australian/
Jebsen-Taylor Hand Function Test, MAP-hand ¼ Measure of Activity Performance,
lder Americans' Resources and Services) Multidimensional Functional Assessment
, SACRAH, VAS ¼ Visual Analog Scale.
Table IV
Supporting evidence from at least 3 studies for the most frequently applied instruments (n  15) for evaluation of pain, physical function or patient global assessment in hand
OA
Reliability Sensitivity to change Feasibility Validity
Questionnaires
AUSCAN61,62 þ þ z þ
FIHOA51,67 þ þ þy þ
VAS pain60 þ þ
Performance-/assessor-based instruments
Grip strength þ* þ þ
Pinch strength þ* þ þ
Tenderness/pain on palpation85 þ* þ þ*
þ ¼ Established evidence.
Abbreviations: AUSCAN ¼ Australian/Canadian Hand OA Index, FIHOA, VAS.
(From Visser AW et al., 201464).
* Supporting evidence in only 2 studies.
y Supporting evidence in only 1 study.
z Not available in public domain.
Table V
The Dreiser functional index for Hand OsteoArthritis (FIHOA)51,67
1 Are you able to turn a key in a lock?
2 Are you able to cut meat with a knife?
3 Are you able to cut cloth or paper with a pair of scissors?
4 Are you able to lift a full bottle with the hand?
5 Are you able to clench your ﬁst?
6 Are you able to tie a knot?
7 For women e Are you able to sew?
For men e Are you able to use a screwdriver?
8 Are you able to fasten buttons?
9 Are you able to write for a long period of time?
10 Would you accept a handshake without reluctance?
Scoring system: 0 ¼ possible without difﬁculty; 1 ¼ possible with slight difﬁculty;
2 ¼ possible with important difﬁculty; 3 ¼ impossible.
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hand OA has been recognized by physicians and has been recently
evidenced by ultrasonography and MRI5,84. Together, the sub-
domains tender joints and soft swollen joints make up the domain
of joint activity; this was agreed upon as a preliminary core
outcome domain during the consensus meeting at OMERACT1212.
Tender joints can be assessed during physical examination as
tender joint count upon palpation, which is the Doyle modiﬁcation
of the Ritchie index85,86. The tender joint count upon palpation is
frequently used in hand OA studies64. Sensitivity to change of the
tender joint count is frequently studied and is good. Although
reliability and validity have been less extensively studied, these
metric properties were shown to be good as well (for summary see
Table IV). During OMERACT12, tender joint count was therefore
endorsed as a preliminary instrument with which to assess joint
activity.
The number and location of peri-articular or soft tissue swell-
ings, sometimes accompanied by redness, can also be assessed
during joint examination. However, at the moment, the metric
properties of the assessment of soft swollen joints in hand OA are
not established. Therefore the evaluation of soft swollen joints is
not mandatory in clinical trials, although the Task Force strongly
encourages it's assessment. For reporting purposes a descriptive
diagram can be used.‘Flares’
The deﬁnition of ‘ﬂares’ and of the ‘number of ﬂares’ lacks
precise description (see above). Moreover, there is no validated
tool currently available to perform this measurement. It is sug-
gested therefore that ‘ﬂares’ should not be used at this time as anoutcome measure. This issue could be explored through further
studies.Hand strength
Also resulting from the consensusmeeting at OMERACT12, hand
strength is deﬁned as a core domain, which is separate from the
core domain physical function, and should be assessed in clinical
trials.
Grip strength and pinch strength are extensively studied in
patients with hand OA. As summarized in a recent systematic
review reliability is good64. Sensitivity to change is good, espe-
cially for grip strength. To study validity, grip strength and pinch
strength have been compared to questionnaires assessing physical
function, showing limited association. However, controlling for
self-reported pain, radiographic OA in speciﬁc locations (CMC
joints, MCP joints, and ray 1) may be at particular risk for reduced
hand strength87. Metric properties are summarized in Table IV.
These observation are in support of the notion that hand strength
is a separate domain from physical function. During OMERACT12,
grip strength and pinch strength were endorsed as preliminary
instruments.Additional domains
Physician assessment of global status
A measure of the physician assessment of global status may be
required in some cases. There is no generally accepted method for
measurement of this variable. A standard question could be used
such as “Considering all the information you have, how is the pa-
tient's hand OA today?”, with responses recorded on a VAS, NRS or
Likert scale. Physician global assessment is not a core set outcome
measurement (Fig. 1).Stiffness
The duration and severity of joint stiffness can be assessed, but
these are also not core set measures. There is currently no standard
wording for questions relating to the duration of joint stiffness in
hand OA. When duration of stiffness is used as an outcome mea-
surement, a standard question is recommended and the following
may be sufﬁcient: “Do you have stiffness in your joints in the
morning” and “What is the duration of stiffness in your ﬁnger joints
in the morning?” (expressed in minutes). When the severity of
stiffness is to be measured in clinical trials, the AUSCAN Index
stiffness subscale may also be used61.
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Concomitant medications, such as analgesic and nonsteroidal
anti-inﬂammatory drug consumption should be carefully recorded
at baseline and at each visit. While rescue medication usage has not
been validated as an outcome for hand OA clinical trials, it certainly
provides important information, and should be carefully recorded
in symptom modiﬁcation clinical trials.
Response criteria
There are no deﬁnitions of minimum clinically important re-
sponses for any of the above measures in OA of the hand. However,
a Minimum Clinically Important Improvement and Patient
Acceptable Symptom State have now been described for pain and
function in hand OA50. These important response criteria should be
systematically incorporated in symptom-modiﬁcation trials to
assess studied treatments at the patient level (which can be
considered the most important, especially in chronic diseases).
Additional research is needed to further develop such responder
criteria speciﬁcally for hand OA studies.
Outcome measures for structure modifying trials
Core domains and their outcomes
For studies of potential structure modifying treatments, the
primary outcome variable should be a measure of structural dam-
age, including the subdomain radiographic damage. Furthermore,
the core set of outcome domains includes the following domains
that are mandatory for symptom modifying clinical trials, namely,
pain, physical function, joint activity, and hand strength. Other
subdomains of structural damage are optional, including aesthetic
damage, bony damage and deformity, and hand mobility, HR-QoL
and patient global assessment12.
Clinical follow up of patients participating in trials of structure-
modifyingdrugsshouldbeconductedat regular intervalsof3months.
Joint imaging
Imaging methods enable the assessment of structural damage.
The plain radiograph remains the most widely available and stan-
dardized method for the evaluation of hand OA. It is anticipated,
that as ultrasonography, MRI and computed tomographic images
becomemore readily available and more affordable, measurements
currently undertaken with joint radiographs will be performed by
one of the modern imaging methods. However, further prospective
studies of ultrasonography, MRI and computed tomography areTable VI
Radiographic scoring systems for hand osteoarthritis
Scoring method No. of joints DIP PIP IP1 MC
Anatomical phases37 26 þ þ þ þ
Anatomical lesions37 24 þ þ  þ
Burnett 18 þ þ  
Eaton129 4    
GUSS130 18 þ þ þ 
Kallman36 22 þ þ þ 
KellgreneLawrence47 30 þ þ þ þ
Kessler131 18 þ þ  
Lane132 22 þ þ þ 
OARSI35 20 þ þ þ 
Abbreviations: CMC1, DIP, GUSS ¼ Gent University scoring system, IP1 ¼ ﬁrst inter
STT ¼ scaphotrapezotrapezoidal joint.
From Visser AW et al., 201488.needed before these modern imaging methods can replace radi-
ography as an instrument to assess structural damage in clinical
trials of structure modiﬁcation of the hand.
Acquisition and reading of radiographs
For structure modifying trials, a postero-anterior radiograph
with the beam focused on the head of the third metacarpal of each
hand on separate cassettes should be obtained. It is recommended
that the radiographs be obtained at the point of enrollment in the
study and again at yearly intervals. A handmap is recommended for
reproducibility of position. A standardized technique should be
used in subsequent acquisitions, for details see elsewhere in this
issue. At a minimum, all trials should include radiographic assess-
ment of all the distal interphalangeal (DIPs), PIPs joints, and the 1st
CMC (carpo-metacarpal or trapeziometacarpal) joints. Unless there
is a special reason, the ﬁrst carpometacarpal (1st CMC) joint does
not need to be imaged separately.
Information about the reading procedure can be found else-
where in this issue.49
Joints examined
The protocol should specify which joints are to be radiograph-
ically evaluated. In some studies this may include up to 16 joints
(one single hand) or 32 joints (both hands), including all inter-
phalangeal joints, MCPs, ﬁrst CMC and scapho-trapezial joints. In
case one hand is evaluated, the trial protocol should describe,
which hand is the index hand and why (e.g., dominant hand, hand
with most complaints, right or left hand).
Currently, there is no consensus regarding how the information
from all the different joints (groups) should be aggregated. Since
the studies performed so far differ largely with respect to the
number of joints examined and the way scores were analyzed or
aggregated, no recommendation can be made on this issue.88
Structural abnormalities to investigate
All trials need to record changes in the selected joints that
reﬂect joint space narrowing and osteophytes89. Additional mea-
surements to be recorded include subchondral erosions, sub-
chondral sclerosis, subchondral cysts and deformity. The protocol
should deﬁne each of these features and how they are to be
recorded. Although osteophytes or joint space narrowing might be
more sensitive to change in the evaluation of progression, mea-
surement of all radiographic features is recommended at this time.
Measurement of the above radiographic features should be
performed by valid, discriminatory (reliable and sensitive to
change) and feasible instruments. Recently, a systematic literature
review was performed and published evaluating the use of radi-
ography in hand OA and assessing the metric properties of theP CMC1 STT Type of score Range of total score
  Composite score 0e218.4
  Composite score Not speciﬁed
þ  Individual features 0e126
þ þ Composite score Not speciﬁed
  Composite score 10e300
þ þ Individual features 0e208
þ  Composite score 0e120
þ  Composite score 0e18
þ þ Individual features 0e182
þ e Individual features 0e198
phalangeal joint, MCP ¼ metacarpophalangeal joint, No. ¼ number, OARSI, PIP,
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different scoring methods were used to assess radiographic hand
OA (Table VI); however some scores have been studied far more
extensively than others. Data on reliability, validity, sensitivity to
change, and feasibility were available, showing that the reliability
of all evaluated scoring methods was good. However, the evidence
for validity of radiographic OA ﬁndings compared to clinical ﬁnd-
ings (nodes and deformities) was limited, whereas evidence for the
association of radiographic ﬁndings with symptoms and hand
function was better. The sensitivity to change and smallest
detectable change were comparable for all evaluated scoring
methods. Feasibility of the different radiographic scoring methods
is only described for a few methods, but showed no major differ-
ences between themethods. Themetric properties are summarized
in Table VII for the most extensively studied scores. In addition, two
studies compared the most used scoring methods in the same
sample of radiographs and did not identify any superiority of one
method above another90,91. It is therefore recommended, depend-
ing on the research question, that the following most commonly
used and currently best validated measures be included in a core
set for structural damage: Kellgren and Lawrence method, OARSI
atlas or Kallman method, or VerbruggeneVeys method35e47.Ultrasonography
Ultrasonography provides dynamic images of hand joints and
allows visualization not only of osteophytes and synovitis, but also
of erosions92,93. Currently, a preliminary ultrasonographic scoring
system based on semi-quantitative scales, is available for hand OA
for assessing ‘grey scale’ synovitis (grey scale hypertrophy with
effusion), ‘grey scale synovitis’ with positive power Doppler signal
and osteophytes94. Recently, a reliable atlas for assessment of
osteophytes by ultrasonography was developed95. Preliminary
studies have shown that validity and sensitivity of ultrasonography
is good when compared to radiography, however more data are
needed before ultrasonography can be used as an instrument to
assess primary outcome measures in clinical trials of hand OA84,96.
However, the Task Force supports the use of ultrasonography as an
instrument to assess exploratory outcomes, to assess not only
structural damage, but also joint activity, including joints with signs
of inﬂammation.Magnetic resonance imaging (MRI)
MRI is capable of visualizing all components of the joint,
including cartilage, synovial membrane and subchondral bonewith
potential bone marrow lesions. A preliminary MRI scoring system
has been developed, which includes assessment of osteophytes,
joint space narrowing, erosions, cysts, malalignment, synovitis,
ﬂexor tenosynovitis, subchondral bone marrow lesions, collateral
ligament pathology and bonemarrow lesions at insertion sites. This
preliminary grading system has been shown to have good intra-and
inter-reader reliability97,98. However, currently knowledge about
validity and sensitivity to change is limited, which precludes theTable VII
Supporting evidence for most frequently applied radiographic scoring methods
Reliability Sensitivity to change Feasibility Validity
Composite score
KL47 þ þ þ þ
Individual features
Anatomical phases37 þ þ þ
OARSI35 þ þ þ þ
Kallman36 þ þ þ
þ ¼ established evidence.
Abbreviations: KL ¼ KellgreneLawrence, OA, OARSI.
Modiﬁed from Visser AW et al. 201488.recommendation of MRI as a primary instrument to assess struc-
tural damage. However, MRI can be used as an instrument to assess
exploratory outcomes evaluating not only structural damage, but
also joint activity. For more details, see elsewhere in this issue.
Aesthetic damage assessment
Several studies in hand OA showed that aesthetic damage,
meaning concern or dissatisfactionwith appearance of the hands as
a result of nodes and deformities in affected hand joints, is present
in male and especially female patients38,99. However research into
aesthetic damage in hand OA is limited. The presence of aesthetic
damage and its impact can be measured with items from a vali-
dated and reliable questionnaire: the MHQ63,100. The metric prop-
erties of the MHQ are however not well studied in patients with
hand OA and need further evaluation. As an alternative a stan-
dardized question was used to address aesthetic damage: “On a
scale of 0e100, howmuch does the appearance of your ﬁnger joints
affect your life” (0 ¼ none, no aesthetic damage; 100 ¼ maximal
affect/aesthetic damage), however this question also needs testing
of its metric properties38,99. Therefore, current assessment of
aesthetic damage is recommended as an optional outcome mea-
sure and not as a core outcome12.
The Task Force recognizes the potential importance of a measure
of aesthetic damage and recommends assessing this domain as an
exploratoryoutcome, until a validated instrument becomes available.
Bony damage and deformity
Bony enlargements at the DIP or PIP joints, so-called Heberden's
nodes and Bouchard's nodes respectively, or at the 1st CMC and
deformities, which may involve malalignment of the distal phalanx
or angular deviation in the thumb base joint, are all aspects of
structural damage of hand OA. However, at the moment no valid
and discriminatory (reliable and sensitive to change) instrument
exists to assess this subdomain. Therefore, bony damage and
deformity are not currently recommended as core outcome mea-
sures. However, to describe the patient population and characterize
its disease severity in trials of structure modiﬁcation, recording is
recommended of the presence of bony enlargements and
deformities.
Hand mobility
Structural abnormalities due to hand OA result in decreased
range of motion of the ﬁngers and difﬁculty in making a ﬁst. Hand
mobility can therefore be used as an outcome measure in structure
modifying trials. No disease speciﬁc instruments exist that assess
hand mobility in hand OA. However, instruments are available that
are especially used and validated in other disease areas but are used
in hand OA as well, such as the Hand Mobility in Scleroderma test
(HAMIS), the ﬁngertip to palm distance during maximal ﬁnger
ﬂexion100e103, the modiﬁed Kapandji index and the Beighton
scoring system104e108. In the modiﬁed Kapandji index, three tests
are summated: ﬁrst the assessment of thumb opposition for each
hand; second the assessment of ﬂexion of the 2nd to 5th digits, and
third the assessment of the digits107. The metric properties of these
tests of hand mobility have not been investigated in hand OA.
Therefore at the moment, hand mobility is only recommended as
an optional outcome measure in clinical trials in hand OA.
Soluble biomarkers
Soluble biomarkers can be categorized according to the OA
process targeted in markers of cartilage degradation or synthesis,
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can be also classiﬁed according to their clinical functionality (BI-
PEDS classiﬁcation) in Burden of disease, Investigative, Prognostic,
Efﬁcacy of Intervention, Diagnostic and Safety biomarkers109. Sol-
uble biomarkers could potentially be useful in clinical trials of hand
OA to deﬁne the patient population, to select patients at risk for
rapid progression or as outcome measures to assess the domains
joint activity and structural damage. Therefore, they could be of use
in both symptom modifying and structure modifying clinical trials
in hand OA.
However, up until now, very few studies have investigated sol-
uble biomarkers and their metric properties in hand OA; also their
clinical relevance is not well understood. Since hand OA is poly-
articular in nature and is often associated with OA in large joints
such as knee and hip, and additional areas, such as in the spine, the
interpretation of soluble biomarkers measured systemically will be
difﬁcult. However, hand OA is often accompanied by inﬂammatory
signs and erosive evolution can be rapid, so soluble biomarkers seem
ideal to provide early and speciﬁc information about disease activity
and severity before clinical and radiographic signs become evident.
The majority of studies that have soluble biomarkers to date,
have been small in number and cross-sectional, and primarily
investigated biomarkers that can be classiﬁed as “Diagnosis” or
“Burden of disease” biomarkers according the BIPEDS classiﬁcation
system110. A variety of biomarkers addressing different tissues of
the joint have beenmeasured (for review see110), includingmarkers
of collagen II degradation (Coll2-1NO2/Coll2-1 ratio, Coll2-3/
4c)111,112, and CTXII110, myeloperoxidase (MPO)111, high sensitivity
C-reactive protein (hsCRP)113, C-telopeptide of type I collagen (CTX-
I)114, hyaluronic acid (HA)110,115,116, soluble interleukin-2 (sIL-2)117,
cartilage oligomeric matrix protein (COMP)115, vascular cell adhe-
sion molecule (VCAM)-1118,119 and Type IIA Collagen N-Propeptide
(PIIANP)112. These biomarkers were especially used to discriminate
non-erosive from erosive hand OA or controls from hand OA110. As
discussed above, at themoment it is not clear whether erosive hand
OA is a separate disease entity, so the value of soluble biomarkers to
deﬁne the patient population is unclear. Longitudinal studies in
hand OA investigating soluble biomarkers are lacking, so their value
in prediction of monitoring of disease is unclear.
The Task Force therefore, currently, does not recommend the
use of soluble biomarkers as a surrogate for clinical outcomes in
clinical trials of hand OA. However, biological ﬂuid collection might
be performed in order to investigate soluble biomarkers as
exploratory or ancillary measures.Conclusion
The purpose of these Task Force recommendations is to provide
evidence-based guidance on the design, execution and analysis of
clinical trials in hand OA, where published evidence is available,
supplemented by expert opinion where evidence is lacking.
Although in recent years more data on the performance of clinical
trials in hand OA has become available, still much work has to be
done. The Task Force hopes that these guidelines will promote in-
terest in and encourage further investigation of instruments and
methodology for the performance of clinical trials in hand OA.Research agenda or what we need to address in the near
future
This agenda lists research questions that seem to most urgently
need to be addressed from the perspective of performing “good”
clinical trials in hand OA. New classiﬁcation criteria for hand OA, including thumb base
OA, interphalangeal OA and erosive OA.
 Development of instrument(s) to assess both constant and
ﬂuctuating hand pain.
 Improved functional assessment.
 Development of instruments to assess health-related quality of
life, number of joints with soft tissue swelling, aesthetic dissatis-
faction/damage, bony damage and deformity, and hand mobility.
 Clariﬁcationofwhichradiographicmethodtouse?Whatandhow
to score on radiographs? Best radiographic reading procedures?
 How to analyze radiographic progression? At patient level? Joint
level?
 Evaluation of modern imaging techniques for hand OA.
 Evaluation of the value of biomarkers in hand OA (especially
clinical relevance).Disclosure
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